K-LYTE 25 mEq (Potassium Citrate) Effervescent Tablets
Natural health product licensed in Canada
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Bicarbonate de potassium Potency : 25 mEq Potassium | 2,500 mg | Not calculated |
| Acide citrique anhydre Source : Maïs | 2,064 mg | Not calculated |
Non-medicinal ingredients
Cellulose microcristalline, Saccharinate de sodium, Mineral oil, Laque d'aluminium jaune FD&C No. 6, Saveur, Talc, FD & C Jaune no. 6
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Comprimé | minimum: 2 Tous les jours ; maximum: 4 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
For therapy or prophylaxis of potassium deficiency.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Patients with impaired mechanisms for excreting potassium, e.g. chronic renal disease, administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given i.v. potassium but may also occur in patients given oral potassium. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. Careful monitoring of the serum potassium concentration and appropriate dosage adjustment is recommended. Caution is advised with concomitant administration of potassium and potassium sparing diuretics e.g. spironolactone or triamterene, since hyperkalemia may develop. Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt such as the acetate, bicarbonate, gluconate or citrate. In patients on a low salt diet particularly, hypokalemic hypochloremic alkalosis is a possibility that may require chloride as well as potassium supplementation. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease or acidosis, requires careful attention to acid base balance and appropriate monitoring of serum electrolytes, the ECG and the patient's clinical status. Use potassium with caution in diseases associated with heart block since increased serum potassium may increase the degree of block.
- Contre-indications
In ventricular fibrillation, hyperkalemia of any etiology, in association with Addison's disease, salt losing adrenal hyperplasia, in extensive tissue breakdown as in severe burns, acute dehydration and heat cramps. Renal impairment with oliguria or azotemia. Increased sensitivity to potassium administration, e.g., in congenital paramyotonia or adynamia episodica hereditaria.
- Effets indésirables connus
Nausea, vomiting and diarrhea have been reported. These symptoms are due to irritation of the gastrointestinal tract and are best avoided by dissolving each dose completely in the stated amount of water, increasing fluid intake when possible, taking the dose with meals or reducing dose.
Product record
- Licence holder
- WellSpring Pharmaceutical Canada Corp.
- NPN or DIN-HM
- 02085992
- Status
- Active licence
- Licence date
- 24 June 2008
- Revision date
- 17 May 2024
- Form
- Comprimé, effervescent
- Route of administration
- Orale
- Application type
- DIN de transition
Source
Official Health Canada record, licence 02085992
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “K-LYTE 25 mEq (Potassium Citrate) Effervescent Tablets”, https://compoatlas.com/en/supplements/canada/02085992-k-lyte-25-meq-potassium-citrate-effervescent-tablets, updated 17 May 2024.